We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00992342
Recruitment Status : Completed
First Posted : October 9, 2009
Last Update Posted : March 18, 2010
Information provided by:

Brief Summary:
The purpose of this study is to investigate safety and toleration of multiple oral doses as well as the time course of PF-03893787 concentration in the blood following dosing by oral solution.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-03893787 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03893787 In Healthy Subjects
Study Start Date : November 2009
Primary Completion Date : March 2010
Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: PF-03893787 5 mg Drug: PF-03893787
oral solution, 5 mg, QD for 14 days
Experimental: PF-03893787 15 mg Drug: PF-03893787
oral solution, 15 mg, QD for 14 days
Experimental: PF-03893787 50 mg Drug: PF-03893787
oral solution, 50 mg, QD for 14 days

Primary Outcome Measures :
  1. Safety/toleration: Adverse events, vital signs, 12 lead ECG, blood (including creatine kinase) and urine safety tests and physical examination. [ Time Frame: 22 days ]

Secondary Outcome Measures :
  1. Pharmacokinetic parameters: Cmax, Tmax, AUCτ, t½, accumulation ratio, [ Time Frame: 22 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects and females of non-childbearing potential between the ages of 18 and 55 years.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 21 drinks/week for males and 14 drinks/week for females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00992342

Pfizer Investigational Site
Bruxelles, Belgium, 1070
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00992342     History of Changes
Other Study ID Numbers: B0281003
First Posted: October 9, 2009    Key Record Dates
Last Update Posted: March 18, 2010
Last Verified: March 2010